Renal Dialysis Articles & Analysis
7 news found
“Kidney transplant recipients are particularly challenged by BK viremia, which puts the survival of their transplanted graft at risk,” said Anil K. Chandraker, MD, Director of Renal Transplant Medicine, Brigham and Women’s Hospital. “We currently manage high-level BK viremia by reducing immunosuppressive therapy, which can help a patient’s immune ...
ByKalaris
Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is approved for the treatment of chronic kidney disease and type 2 diabetes, excluding patients with end-stage renal disease or on dialysis. The approval is based on the results of the pivotal Phase III studies, FIDELIO-DKD and FIGARO-DKD. ...
ByBayer AG
BKV is detected in up to 20% of kidney transplant patients and can lead to graft loss and a return to end-stage renal disease and dialysis. There are no approved or effective BKV treatments. ...
ByKalaris
” The Furosemide Stress Test (FST) is commonly used in the critical care setting to gauge the likelihood that a patient with early-stage acute kidney injury will progress to more severe stages resulting in major, costly interventions that include readmissions, renal replacement therapy, permanent dialysis and mortality. Traditionally, the FST requires the ...
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of Avenu Medical, a privately held medical device company based in San Juan Capistrano, Calif. focused on the endovascular (minimally invasive) creation of arteriovenous (AV) fistulae for patients with end-stage renal disease (ESRD) undergoing dialysis. ...
Invizius, the University of Edinburgh spin-out which is developing potentially lifesaving products for dialysis patients, has made four high-profile appointments as it prepares to enter the next stage of its development. ...
There are millions of patients worldwide with End-Stage Renal Disease (ESRD) that require dialysis to sustain life. Though an AV fistula is the preferred and most cost-effective method for vascular access, the procedure is plagued with high short- and long-term failure rates. Up to 50% of AV fistulae suffer primary failure and are never used because they do not ...